Kriya Therapeutics is a next-generation gene therapy company that designs and develops transformative new treatments for highly prevalent and severe chronic diseases. The company targets conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate human tissues. Kriya's team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. The company uses a vector design platform to strengthen the capability to undertake de novo construct design, targeted sequence modification, and data analysis, enabling physicians to minimize immunogenicity and improve tissue specificity. Kriya is built on two distinct technology platforms: its computationally enabled proprietary platform for rational vector design (SIRVE™) and its innovative high-efficiency manufacturing platform for scalable and low-cost production (STRIPE™). The company is advancing a deep and diversified pipeline of innovative gene therapies spanning rare and prevalent diseases in multiple therapeutic verticals, with current pipeline programs addressing metabolic, ophthalmic and oncologic diseases.